Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B

World Journal of Gastroenterology

Volumn 20, Issue 30, 2014, Pages 10585-10590

  Wang, Chun Yan ^a   Lu, Wei ^a   Hu, Dong Sheng ^a   Wang, Guang Dong ^b   Cheng, Xiao Jing ^c  

^a TIANJIN SECOND PEOPLE S HOSPITAL   (China)

^b Rizhao Chinese Medical Hospital   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Controlled attenuation parameter; Liver steatosis; Transient elastography

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED ATTENUATION PARAMETER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY ASSESSMENT; ELASTOGRAPHY; FATTY LIVER; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY; AREA UNDER THE CURVE; BIOPSY; COMPLICATION; ELASTICITY; HEPATITIS B, CHRONIC; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOPSY; ELASTICITY; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84920601209     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i30.10585     Document Type: Article

References (23)

1. Farrell GC. Fatty liver disease: NASH and related disorders. Malden (MA): Blackwell Publishing, 2004
2. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, Miette V. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-1835 [PMID: 20870345 DOI: 10.1016/j.ultrasmedbio.2010.07.005]
3. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (Version 2010). Zhonghua Shiyan He Linchuang Ganranbing Zazhi 2011; 29: 65-80
4. Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC, Balart LA, Ortego TJ, Payne J, Dienstag JL. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993; 104: 595-603 [PMID: 8425703]
5. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-1832 [PMID: 8253358]
6. Shi JP, Fan JG. Advances in researches on relationship of steatosis with hepatitis B virus infection. Guoji Xiaohuabing Zazhi 2008; 2: 100-102
7. Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826 [PMID: 15382171]
8. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36: 13-20 [PMID: 21920839 DOI: 10.1016/j.clinre.2011.08.001]
9. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
10. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117 [PMID: 10644271 DOI: 10.7326/0003-4819 -132-2-200001180-00004]
11. Sussman S, Dent CW, Skara S, de Calice P, Tsukamoto H. Alcoholic liver disease (ALD): a new domain for prevention efforts. Subst Use Misuse 2002; 37: 1887-1904 [PMID: 12511057 DOI: 10.1081/JA-120016223]
12. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642 [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014]
13. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 399-408 [PMID: 17311652]
14. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 5-13 [PMID: 15962320 DOI: 10.1002/hep.20750]
15. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]
16. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 Suppl 4: IV1-IV11 [PMID: 10485854 DOI: 10.1136/gut.45.2008.iv1]
17. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-445 [PMID: 19604596 DOI: 10.1016/j.jhep.2009.05.023]
18. Mancini M, Prinster A, Annuzzi G, Liuzzi R, Giacco R, Medagli C, Cremone M, Clemente G, Maurea S, Riccardi G, Rivellese AA, Salvatore M. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism 2009; 58: 1724-1730 [PMID: 19716568 DOI: 10.1016/j.metabol.2009.05.032]
19. Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta 2009; 1790: 663-670 [PMID: 18848602]
20. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-253 [PMID: 22404722 DOI: 10.1111/j.1365-2893.2011.01534.x]
21. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, Duarte-Rojo A, Wong D, Crotty P, Elkashab M. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902-910 [PMID: 22435761 DOI: 10.1111/j.1478-3231.2012.02781.x]
22. Boursier J, Calès P. Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat? Liver Int 2012; 32: 875-877 [PMID: 22672640 DOI: 10.1111/j.1478-3231.2012.02824. x]
23. de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-918 [PMID: 22672642 DOI: 10.1111/j.1478-3231.2012.02820.x]